Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development
I'm PortAI, I can summarize articles.
Wuxi Biologics (Cayman) Inc. has launched a global CRDMO platform to enhance biologics development. The platform offers comprehensive services across the biologics lifecycle, including monoclonal antibodies and viral vaccines. Key achievements include over 600 IND submissions, 25 commercial programs, and 74 Phase III projects, with high reliability metrics: 98.3% DS success rate and 100% success rate in regulatory inspections. The flexible service model allows global clients to access tailored contract services in research, development, and manufacturing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments